Kairos Pharma (KAPA) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing therapeutics for cancer patients targeting immune suppression and drug resistance.

• No products approved for sale and no revenue from product sales to date.

• Operations include business planning, capital raising, technology development, and preclinical/clinical studies.

• Substantial additional funding required to support ongoing operations and growth strategy.

Financial performance and metrics

• Net losses of $4.1 million for the nine months ended September 30, 2025, and $2.6 million for the year ended December 31, 2024.

• Accumulated deficit of approximately $12.9 million as of September 30, 2025.

• Public float as of January 12, 2026, was approximately $13.6 million based on 13,994,687 shares at $0.97 per share.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including research and clinical development, working capital, capital expenditures, and potential acquisitions or in-licensing.

• Management retains broad discretion over allocation of net proceeds.

• Proceeds may be temporarily invested in short-term, investment-grade instruments or held as cash.